)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Biomea Fusion
Biomea Fusion (BMEA) investor relations material
Biomea Fusion Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary10 Nov, 2026
Executive summary
COVALENT-211 enrollment is complete and COVALENT-212 enrollment continues; primary data are expected in Q1 and Q2 2027, respectively.
Phase I BMF-650 results showed early weight reduction with generally favorable tolerability; cash runway is projected into Q2 2027.
Financial highlights
Q3 2026 net loss was $6.2M vs. $16.4M a year earlier, partly reflecting a $6.5M noncash gain from warrant-liability revaluation.
Q3 R&D expense was $8.5M vs. $14.4M; G&A was $4.4M vs. $4.2M; total operating expenses were $13.0M vs. $20.8M.
9M 2026 net loss was $26.9M vs. $66.4M; operating expenses were $38.5M vs. $71.8M.
Cash, cash equivalents and restricted cash were $26.8M at September 30, 2026, vs. $56.2M at December 31, 2025; 9M operating cash use was $30.1M vs. $56.4M.
Outlook and guidance
COVALENT-211 Week 26 primary HbA1c data are expected in Q1 2027; COVALENT-212 Week 26 data are expected in Q2 2027, followed by 52-week secondary data.
OPAL assesses its primary endpoint at Week 24, with topline data anticipated at the end of 2027.
Cash is expected to fund operations into Q2 2027; additional capital is required to continue operations and planned development.
R&D expenses and operating losses are expected to rise as icovamenib trials continue and BMF-650 advances; further BMF-650 development requires longer-term toxicology studies.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Biomea Fusion
- BMF-650 produced 6.1% four-week weight loss at 400 mg QD, with no serious TEAEs.BMEA
Study result - Promising phase II diabetes results and next-gen GLP-1 data set for major readouts this year.BMEAH.C. Wainwright 28th Annual Global Investment Conference
- Novel oral therapies show promise for diabetes and obesity with key Phase II data ahead.BMEACorporate presentation
- Icovamenib and BMF-650 show promise for durable diabetes and obesity treatment innovation.BMEACorporate presentation
- Net loss narrowed, but liquidity concerns persist as cash runway extends only into Q2 2027.BMEAQ2 2026
- Promising diabetes therapies advance with pivotal data and partnership-driven development ahead.BMEAPiper Sandler 37th Annual Healthcare Conference
- Directors and auditors were approved by majority vote, with results to be filed with the SEC.BMEAAGM 2026
- Icovamenib achieved robust HbA1c reduction and strong safety in insulin-deficient type 2 diabetes.BMEAStudy Result
- BMF-500 demonstrated early efficacy and strong safety in relapsed/refractory acute leukemia.BMEAStudy Update
Next Biomea Fusion earnings date
Q4 202629 Mar, 2027
Biomea Fusion
Next Biomea Fusion earnings date
Q4 202629 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Biomea Fusion Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery and development of covalent small molecule drugs. These drugs are designed to treat patients with genetically defined cancers and metabolic diseases. The company’s approach leverages covalent bonding, where a small molecule forms a permanent bond with its target protein, which may offer advantages like greater target selectivity and a more durable therapeutic response. The company is headquartered in Redwood City, California, and its shares are listed on the NASDAQ.